 |
Samuel Goldhaber, MD
Professor of Medicine
Harvard Medical School
Director of the Anticoagulation Service
Director of the Venous Thrombooembolism Research Group
Samuel Z. Goldhaber, MD, Professor of Medicine at Harvard Medical School, chairs the Venous Disease Coalition. Dr. Goldhaber is a Senior Staff Member of the Cardiovascular Medicine Division of Brigham and Women's Hospital (BWH). He is Director of the BWH Venous Thromboembolism Research Group and serves as Principal Investigator of a broad range of randomized clinical trials and observational studies related to the prevention, treatment, and epidemiology of venous thromboembolism. Dr. Goldhaber is also Director of the BWH Anticoagulation Service, which cares for more than 2,000 patients.
The March 10, 2005, New England Journal of Medicine published his large clinical trial that described a new method using electronic alerts to enhance venous thromboembolism prophylaxis. This intervention reduced symptomatic DVT and PE by 41%, without an increase in bleeding complications. Dr. Goldhaber is also the Principal Investigator of an ongoing multicenter trial on Physician Alerts for patients at high risk of DVT or PE who are not receiving prophylaxis.
In May 2006, he co-chaired the 2-day Surgeon General's Workshop on DVT, which was cosponsored by the National Heart Lung and Blood Institute (NHLBI). He also serves on the National Comprehensive Cancer Network and National Quality Forum to formulate new treatment and prevention guidelines for venous thromboembolism. He is President and one of four Founding Directors of the nonprofit North American Thrombosis Forum (www.NATFonline.org), one of the 19 organizations comprising the Venous Disease Coalition.
Dr Goldhaber co-directs 3 Harvard Medical School continuing medical education courses: 1) a 5-day course reviewing all aspects of cardiovascular medicine, 2) a 2-day course reviewing arterial and venous thrombosis and thromboembolism, and 3) a 1-day course that focuses on thrombosis prevention. He is an editorial board member of several journals, including Circulation.
Ruth B. Morrison, RN, BSN, CVN
Brigham and Women's Hospital
Clinical Research Coordinator
Venous Thromboembolism Research Group
Ruth Morrison, RN, BSN, CVN, is a graduate of Southeastern Massachusetts University where she received her Bachelor of Science in Nursing, going on to receive a certification in Vascular Nursing. Ms. Morrison is a Clinical Research coordinator with the Venous Thromboembolism Research Group at Brigham and Women's Hospital in Boston, MA.
Ms. Morrison has been involved with numerous clinical trials that focus on the prevention, diagnosis, and treatment of deep vein thrombosis and pulmonary embolism. She participated in clinical trials leading to the FDA approval of thrombolytic therapy for the treatment of pulmonary embolism and clinical trials leading to the outpatient treatment of deep vein thrombosis with low-molecular weight heparin. More recently, she participated in the National Institutes of Health sponsored PREVENT Trial, and DVT FREE, the largest prospective registry of DVT.
She is a long-standing member of the Massachusetts Nurses' Association, the American Nurse Association, and the Society of Vascular Nursing. In 2000, Ms. Morrison became a Council Member for Leadership on Thrombosis Awareness and Management. Most recently, she was appointed to the Technical Advisory Panel for the Joint Commission on Accreditation of Healthcare Organizations and National Quality Forum.
Ms. Morrison has published articles in numerous journals including the Journal of Vascular Nursing and Circulation. She has presented nationally at scientific and professional symposia on such topics as the clinical challenge of Factor V Leiden and the pathophysiology and prevention of the sequelae of deep vein thrombosis.
Sylvia McKean, MD
Chief, Hospitalist Service
Brigham and Women's Hospital
Assistant Professor of Medicine
Harvard Medical School
Sylvia McKean, MD is the Medical Director of the BWF Hospitalist Service that cares for inpatients at Brigham and Women's Hospital in Boston, and the Faulkner Hospital in Jamaica Plain, Massachusetts. Her academic appointment is Associate Professor of Medicine at Harvard Medical School and Associate Physician at Brigham and Women's Hospital. Sylvia McKean, M.D. is a scholar in the Harvard Medical School Academy.
Sylvia McKean has had leadership roles in the development of new hospitalist programs for Harvard Vanguard Medical Associates, a managed care organization in Boston, Massachusetts, (1996-1998), Brigham and Women's Hospital, a tertiary care teaching institution, (1998 - present), and Faulkner Hospital, a community hospital, (1999 - present). She has a background in Nephrology and has worked as a General Internist, an Emergency Medicine physician, and a specialist in Vascular Medicine and Hypertension prior to becoming a Hospitalist. In 1996, she implemented an outpatient DVT program with colleagues at Harvard Vanguard Medical Associates.
Over the past ten years, Dr. McKean has received more than a dozen awards for leadership, excellence and teaching, including the prestigious George W. Thorn Award (1997-1998) for outstanding contribution to clinical education from Brigham and Women's Hospital. In 2002, she was appointed "scholar" as a charter member of the Harvard Medical School (HMS) Academy in recognition of excellence in medical education and commitment to improvement and innovation in medical education. She was nominated for Harvard Medical School's 2005 Faculty Prize for Excellence in Teaching and elected a Fellow of the American College of Physicians in 2005. She received the Society of Hospital Medicine's 2006 Excellence in Teaching Award in recognition of outstanding teaching in hospital medicine.
James B. Groce III, PharmD, CACP
Associate Professor,
Department of Pharmacy Practice
Campbell University School of Pharmacy
Clinical Assistant Professor of Medicine
UNC School of Medicine
Clinical Pharmacy Specialist-Anticoagulation
Moses H. Cone Memorial Hospital
James B. Groce III, PharmD, is Professor, Department of Pharmacy Practice at Campbell University School of Pharmacy. He also is Clinical Assistant Professor of Medicine at the University of North Carolina School of Medicine and Clinical Pharmacy Specialist-Anticoagulation at the Moses H. Cone Memorial Hospital in Greensboro, North Carolina.
He served as principal investigator at Moses H. Cone Health System for DVT FREE, a national registry trial examining risk factors and prevalence of DVT. Additionally, he was part of the 11 member steering committee for this imitative. He was one of 20 principal investigators for a national cohort study on bridging patients onto LMWH who required interruption of their chronic anticoagulant therapy. He represents pharmacy nationally on the Council for Leadership on Thrombosis Awareness and Management (CLOT Council) as its sole pharmacist member on this physician-based panel of National thought leaders and experts on thromboembolism as well as the Coalition Against DVT in the same capacity. He was recently appointed to the Technical Advisory Panel of JCAHO/NQF for creation of core measures for prevention and treatment of venous thromboembolism. Most recently, he was named Preceptor of The Year by the graduating class of 2006, Campbell University School of Pharmacy.
Among his extensive research activities, Dr. Groce served as principal investigator of a pharmacoeconomic evaluation of the use of LMWH for outpatient therapy of DVT in a community teaching hospital setting. He also has conducted clinical evaluations of various heparin weight-based-dosing nomograms, the utility of heparin level determinations and outcomes analysis, comparison of bedside point-of-care testing to standard laboratory tests (e.g., PT/INR, aPTT, and heparin levels), and warfarin dosing software validation. He has been published and cited in peer-reviewed medical and pharmacy journals as well as textbooks of pharmacy.
He has presented extensively regarding the interchange of Narrow Therapeutic Index Drugs and its impact with respect to efficacy and safety, and pharmacoeconmics; he gave testimony before the state Senate and House Subcommittees of the North Carolina Legislature examining this issue that resulted in Senate Bill 945-The Prescription Refill Safety Act.
Dr. Groce is certified by the National Certification Board of Anticoagulation Providers and currently is a sitting member of its Board of Directors. He currently manages an anticoagulation clinic serving over 100 patients and supervises pharmacy practice and medicine residents training in anticoagulation management at this site. He has served as chairperson of the Carolinas Anticoagulation ReSource group (CARS) an organization of over 200 physicians, pharmacists, nurses and laboratorians in the two Carolinas who specialize in providing anticoagulation management services. |
|
|
It is the policy of ArcMesa Educators to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty/authors are expected to disclose any relevant financial relationships they may have with commercial interests in relation to this activity. These relationships, along with the educational content of this program, have been reviewed and any potential conflicts of interest have been resolved to the satisfaction of ArcMesa Educators.
Samuel Goldhaber, MD
Clinical Research: Sanofi-Aventis, Eisai, GlaxoSmithKlein, Mitsubishi, and Boehringer Ingelheim
Consultant: Sanofi-Aventis, Eisai, Boehringer Ingelheim, Bristol-Myers Squibb, and Canyon
Ruth B. Morrison, RN, BSN, CVN
Speakers' Bureau: Sanofi-Aventis
James B. Groce III, PharmD, CACP
Consultant, Honorarium Recipient: Eisai Pharmaceuticals, The Medicine Company, Diagnostica-Stago
Consultant, Honorarium Recipient, Speakers' Bureau - Sanofi-Aventis
Sylvia McKean, MD
Honorarium Recipient: Sanofi-Aventis.
The employees of ArcMesa Educators have no financial relationships to disclose.
Printer settings may vary. Please use landscape layout option.
. |
|
